187 related articles for article (PubMed ID: 38113403)
21. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
22. Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis.
McKinzie CJ; Doligalski CT; Lobritto SJ; Coakley RD; Gower WA
J Cyst Fibros; 2022 Mar; 21(2):227-229. PubMed ID: 34384711
[No Abstract] [Full Text] [Related]
23. Elexacaftor/Ivacaftor/Tezacaftor: First Approval.
Hoy SM
Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874
[TBL] [Abstract][Full Text] [Related]
24. Triple Therapy for Cystic Fibrosis
Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
[TBL] [Abstract][Full Text] [Related]
25. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
[TBL] [Abstract][Full Text] [Related]
26. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
27. Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population.
Smith S; Borchardt M
J Manag Care Spec Pharm; 2022 Jul; 28(7):721-731. PubMed ID: 35737861
[No Abstract] [Full Text] [Related]
28. Assessing Safety of Discontinuing Hypertonic Saline in Those with Lower Forced Expiratory Volume in 1 Second after Elexacaftor/Tezacaftor/Ivacaftor.
Nichols D; Gifford A; Russell R; Odem-Davis K; Young J; Amaro-Galvez R; Billings J; Mukadam Z; Mayer-Hamblett N
Ann Am Thorac Soc; 2024 Feb; 21(2):360-362. PubMed ID: 38019099
[No Abstract] [Full Text] [Related]
29. Neuropsychiatric symptoms with elexacaftor/tezacaftor/ivacaftor: What does this mean for children?
Pham H; Vandeleur M; Ranganathan S
Pediatr Pulmonol; 2024 Mar; 59(3):537-539. PubMed ID: 37991124
[No Abstract] [Full Text] [Related]
30. Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis.
Furstova E; Dousova T; Beranek J; Libik M; Fila L; Modrak M; Cinek O; Macek M; Drevinek P
J Cyst Fibros; 2022 Mar; 21(2):243-245. PubMed ID: 34348870
[TBL] [Abstract][Full Text] [Related]
31. Elexacaftor/tezacaftor/ivacaftor for CFTR variants giving rise to diagnostic uncertainty: Personalised medicine or over-medicalisation?
Salvatore D; Pepe A; Carnovale V; Majo F; Padoan R; Quattrucci S; Salvatore M; Taruscio D; Amato A; Ferrari G; Campagna G
J Cyst Fibros; 2022 May; 21(3):544-548. PubMed ID: 34583889
[No Abstract] [Full Text] [Related]
32. Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor.
Lowry S; Mogayzel PJ; Oshima K; Karnsakul W
J Cyst Fibros; 2022 Mar; 21(2):e99-e101. PubMed ID: 34275759
[No Abstract] [Full Text] [Related]
33. Change in Lung Function after Initiation of Elexacaftor-Tezacaftor-Ivacaftor: Do Not Forget Anatomy!
Martin C; Regard L; Chassagnon G; Burgel PR
Am J Respir Crit Care Med; 2022 Jun; 205(11):1365-1366. PubMed ID: 35358030
[No Abstract] [Full Text] [Related]
34. Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.
Vonk SEM; Lub R; Weersink EJM; Beuers U; Mathôt RAA; Kemper EM; Altenburg J;
Clin Ther; 2024 Feb; 46(2):154-158. PubMed ID: 38042631
[TBL] [Abstract][Full Text] [Related]
35. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
36. Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.
Martin C; Burnet E; Ronayette-Preira A; de Carli P; Martin J; Delmas L; Prieur B; Burgel PR
Respir Med Res; 2021 Nov; 80():100829. PubMed ID: 34091202
[TBL] [Abstract][Full Text] [Related]
37. Elexacaftor/Tezacaftor/Ivacaftor as a Bridge to Lung Retransplant in a Recipient With Cystic Fibrosis.
FitzMaurice TS; Nazareth D; Iyer K; Walshaw M; Al-Aloul M
Exp Clin Transplant; 2022 Apr; 20(4):433-435. PubMed ID: 35297329
[TBL] [Abstract][Full Text] [Related]
38. Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: Decline in HbA1c after elexacaftor/tezacaftor/ivacaftor treatment.
Nielsen BU; Olsen MF; Mabuza Mathiesen IH; Pressler T; Ritz C; Katzenstein TL; Olesen HV; Skov M; Jensen-Fangel S; Almdal TP; Faurholt-Jepsen D
J Cyst Fibros; 2024 Jan; 23(1):103-108. PubMed ID: 37989700
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease.
Terlizzi V; Colangelo C; Marsicovetere G; D'Andria M; Francalanci M; Innocenti D; Masi E; Avarello A; Taccetti G; Amato F; Comegna M; Castaldo G; Salvatore D
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440351
[TBL] [Abstract][Full Text] [Related]
40. Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor.
Ferreira FC; Buarque CD; Lopes-Pacheco M
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
